Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: UCB Inc.
Current Parent Company: UCB
Parent at the Time of the Penalty Announcement:  subscribe to see this data field
Penalty: $34,000,000
Year: 2011
Date: June 9, 2011
Offense Group: healthcare-related offenses
Primary Offense: off-label or unapproved promotion of medical products
Mega-Scandal: Improper Drug Marketing
Violation Description: The U.S. subsidiary of Belgian pharmaceutical manufacturer UCB SA. pleaded guilty to the off-label promotion of its epilepsy drug Keppra and will pay more than $34 million to resolve criminal and civil liability arising out of its illegal conduct.
Level of Government: federal
Action Type: agency action
Agency: Food and Drug Administration referral to the Justice Department
Civil or Criminal Case: civil and criminal
HQ Country of Current Parent: Belgium
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.